고콜레스테롤혈증 치료 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 질환 유형별, 치료 유형별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Hypercholesterolemia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Treatment Type, By End User, By Region and Competition, 2020-2030F
고콜레스테롤혈증 치료 세계 시장 규모는 2024년 213억 8,000만 달러에서 2030년에는 338억 1,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 성장률(CAGR)은 7.91%를 보일 것으로 예측됩니다.
이러한 성장 궤적은 심혈관 질환의 유병률 증가와 콜레스테롤 수치 상승으로 진단받는 세계 인구 증가에 기인합니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
213억 8,000만 달러 |
| 시장 규모 : 2030년 |
338억 1,000만 달러 |
| CAGR : 2025-2030년 |
7.91% |
| 급성장 부문 |
병원 |
| 최대 시장 |
북미 |
건강에 해로운 식습관, 좌식 생활습관, 유전적 소인은 고콜레스테롤혈증 발병률 증가의 주요 요인 중 하나입니다. LDL(저밀도 지단백) 콜레스테롤 수치 상승에 따른 건강 위험(심장마비, 뇌졸중, 말초동맥질환 등)에 대한 대중의 인식이 높아짐에 따라 효과적인 치료 솔루션에 대한 수요가 증가하고 있으며, 조기 진단과 신속한 치료 개입의 중요성이 강조되고 있습니다.
또한, 공공 및 민간 의료 이니셔티브의 강력한 지원으로 검진 프로그램이 확대되고 정기적인 콜레스테롤 검사가 권장되고 있습니다. 이러한 프로그램은 개인이 적극적으로 의사의 도움을 받아 적절한 치료법을 선택하도록 장려하고 있습니다.
시장 성장 촉진요인
고콜레스테롤혈증 유병률 상승
시장의 과제
높은 치료비
시장 동향
의약품 연구 발전
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 고콜레스테롤혈증 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 질환 유형별(유전성 고콜레스테롤혈증, 후천성 고콜레스테롤혈증)
- 치료 유형별(Statins, PCSK9 Inhibitors, Ezetimibe, Bile Acid. Sequestrants, Niacin, Bempedoic Acid, 기타)
- 최종사용자별(병원, 전문 심장 센터, 기타)
- 기업별(2024년)
- 지역별
- 시장 맵
제6장 북미의 고콜레스테롤혈증 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제7장 유럽의 고콜레스테롤혈증 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 고콜레스테롤혈증 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 고콜레스테롤혈증 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 고콜레스테롤혈증 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
제11장 시장 역학
제12장 시장 동향과 발전
제13장 PESTEL 분석
제14장 Porter의 Five Forces 분석
- 업계내 경쟁
- 신규 참여 가능성
- 공급업체의 힘
- 고객의 힘
- 대체품의 위협
제15장 경쟁 구도
- Amgen Inc
- Amryt Pharma plc
- AstraZeneca Plc.
- Regeneron Pharmaceuticals, Inc.
- Novartis Pharmaceuticals Corporation
- Teva Pharmaceutical Industries Ltd.
- Cipher Pharmaceuticals Inc.
- Pfizer Inc.
- Merck & Co., Inc.
- Sun Pharmaceutical Industries Limited
제16장 전략적 제안
제17장 리서치사에 대해 & 면책사항
LSH
Global Hypercholesterolemia treatment market was valued at USD 21.38 billion in 2024 and is projected to reach USD 33.81 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.91% during the forecast period. This growth trajectory is largely attributed to the increasing prevalence of cardiovascular diseases and a rising global population diagnosed with elevated cholesterol levels.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 21.38 Billion |
| Market Size 2030 | USD 33.81 Billion |
| CAGR 2025-2030 | 7.91% |
| Fastest Growing Segment | Hospitals |
| Largest Market | North America |
Unhealthy dietary habits, sedentary lifestyles, and genetic predispositions are among the key factors contributing to the growing incidence of hypercholesterolemia. These conditions are fueling demand for effective treatment solutions. Increased public awareness regarding the health risks associated with elevated LDL (low-density lipoprotein) cholesterol-such as heart attacks, strokes, and peripheral arterial disease-has underscored the importance of early diagnosis and prompt therapeutic intervention.
Furthermore, robust support from both public and private sector healthcare initiatives has led to expanded screening programs and greater advocacy for routine cholesterol testing. These programs are encouraging individuals to proactively seek medical guidance and appropriate treatment options.
Market Drivers
Rising Prevalence of Hypercholesterolemia
The global rise in hypercholesterolemia cases is strongly linked to evolving lifestyle and dietary trends. Sedentary routines combined with high intake of saturated fats and processed foods have significantly increased the number of individuals with high cholesterol levels. According to the World Health Organization (WHO), in 2008, the global prevalence of raised total cholesterol among adults stood at 39% (37% among males and 40% among females), highlighting the widespread nature of this health issue.
Additionally, the global population is aging at a rapid pace. The United Nations Department of Economic and Social Affairs projects that the population aged 65 and older will reach 1.5 billion by 2050, up from 703 million in 2019. Aging is associated with a decline in the body's efficiency in metabolizing and regulating cholesterol, thereby increasing vulnerability to hypercholesterolemia.
Market Challenges
High Cost of Treatment
One of the most pressing challenges in the hypercholesterolemia treatment market is the high cost of therapies, which can hinder access to care and negatively impact patient outcomes. As a chronic condition, hypercholesterolemia typically requires long-term treatment, adding to the financial burden on both patients and healthcare systems.
Although several treatment options are available-including statins and newer agents such as PCSK9 inhibitors-their cost can be prohibitively high, especially for patients without comprehensive insurance coverage. This often leads to delayed treatment initiation, suboptimal adherence, and increased risk of cardiovascular complications.
The economic burden is further compounded by healthcare disparities, particularly among low-income populations who may struggle to afford necessary medications and follow-up care. Consequently, these financial obstacles contribute to unequal access to care and exacerbate existing public health challenges.
Healthcare systems and insurers also face strain from the high cost of providing widespread access to advanced cholesterol-lowering therapies. This pressure may result in limitations on coverage, reduced treatment availability, and compromised quality of care.
Market Trends
Advancements in Pharmaceutical Research
Innovations in pharmaceutical research are significantly advancing the global hypercholesterolemia treatment landscape. While statins have long served as the standard of care, recent developments have introduced novel therapeutic options that are reshaping the market.
Among the most notable innovations is the emergence of PCSK9 inhibitors, which provide an alternative mechanism for lowering LDL cholesterol, particularly in patients who do not respond adequately to statin therapy. These biologics target a specific protein involved in cholesterol regulation, offering enhanced efficacy for certain patient groups.
Ongoing research is also yielding drugs with improved safety profiles and fewer side effects, addressing concerns associated with traditional therapies such as muscle pain. These developments have led to a broader range of treatment options, improving patient compliance and clinical outcomes.
Key Market Players
- Amgen Inc
- Amryt Pharma plc
- AstraZeneca Plc.
- Regeneron Pharmaceuticals, Inc.
- Novartis Pharmaceuticals Corporation
- Teva Pharmaceutical Industries Ltd.
- Cipher Pharmaceuticals Inc.
- Pfizer Inc.
- Merck & Co., Inc.
- Sun Pharmaceutical Industries Limited
Report Scope:
In this report, the Global Hypercholesterolemia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Hypercholesterolemia Treatment Market, By Disease Type:
- Genetic Hypercholesterolemia
- Acquired Hypercholesterolemia
Hypercholesterolemia Treatment Market, By Treatment Type:
- Statins
- PCSK9 Inhibitors
- Ezetimibe
- Bile Acid Sequestrants
- Niacin
- Bempedoic Acid
- Others
Hypercholesterolemia Treatment Market, By End User:
- Hospitals & Clinics
- Ambulatory Care Centres
- Others
Hypercholesterolemia Treatment Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Hypercholesterolemia Treatment Market.
Available Customizations:
Global Hypercholesterolemia Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Hypercholesterolemia Treatment Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Disease Type (Genetic Hypercholesterolemia, Acquired Hypercholesterolemia)
- 5.2.2. By Treatment Type (Statins, PCSK9 Inhibitors, Ezetimibe, Bile Acid Sequestrants, Niacin, Bempedoic Acid, Others)
- 5.2.3. By End User (Hospitals, Specialty Cardiac Centres, Others)
- 5.2.4. By Company (2024)
- 5.2.5. By Region
- 5.3. Market Map
6. North America Hypercholesterolemia Treatment Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Disease Type
- 6.2.2. By Treatment Type
- 6.2.3. By End User
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Hypercholesterolemia Treatment Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Disease Type
- 6.3.1.2.2. By Treatment Type
- 6.3.1.2.3. By End User
- 6.3.2. Mexico Hypercholesterolemia Treatment Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Disease Type
- 6.3.2.2.2. By Treatment Type
- 6.3.2.2.3. By End User
- 6.3.3. Canada Hypercholesterolemia Treatment Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Disease Type
- 6.3.3.2.2. By Treatment Type
- 6.3.3.2.3. By End User
7. Europe Hypercholesterolemia Treatment Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Disease Type
- 7.2.2. By Treatment Type
- 7.2.3. By End User
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Hypercholesterolemia Treatment Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Disease Type
- 7.3.1.2.2. By Treatment Type
- 7.3.1.2.3. By End User
- 7.3.2. Germany Hypercholesterolemia Treatment Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Disease Type
- 7.3.2.2.2. By Treatment Type
- 7.3.2.2.3. By End User
- 7.3.3. United Kingdom Hypercholesterolemia Treatment Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Disease Type
- 7.3.3.2.2. By Treatment Type
- 7.3.3.2.3. By End User
- 7.3.4. Italy Hypercholesterolemia Treatment Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Disease Type
- 7.3.4.2.2. By Treatment Type
- 7.3.4.2.3. By End User
- 7.3.5. Spain Hypercholesterolemia Treatment Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Disease Type
- 7.3.5.2.2. By Treatment Type
- 7.3.5.2.3. By End User
8. Asia-Pacific Hypercholesterolemia Treatment Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Disease Type
- 8.2.2. By Treatment Type
- 8.2.3. By End User
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Hypercholesterolemia Treatment Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Disease Type
- 8.3.1.2.2. By Treatment Type
- 8.3.1.2.3. By End User
- 8.3.2. India Hypercholesterolemia Treatment Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Disease Type
- 8.3.2.2.2. By Treatment Type
- 8.3.2.2.3. By End User
- 8.3.3. South Korea Hypercholesterolemia Treatment Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Disease Type
- 8.3.3.2.2. By Treatment Type
- 8.3.3.2.3. By End User
- 8.3.4. Japan Hypercholesterolemia Treatment Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Disease Type
- 8.3.4.2.2. By Treatment Type
- 8.3.4.2.3. By End User
- 8.3.5. Australia Hypercholesterolemia Treatment Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Disease Type
- 8.3.5.2.2. By Treatment Type
- 8.3.5.2.3. By End User
9. South America Hypercholesterolemia Treatment Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Disease Type
- 9.2.2. By Treatment Type
- 9.2.3. By End User
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Hypercholesterolemia Treatment Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Disease Type
- 9.3.1.2.2. By Treatment Type
- 9.3.1.2.3. By End User
- 9.3.2. Argentina Hypercholesterolemia Treatment Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Disease Type
- 9.3.2.2.2. By Treatment Type
- 9.3.2.2.3. By End User
- 9.3.3. Colombia Hypercholesterolemia Treatment Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Disease Type
- 9.3.3.2.2. By Treatment Type
- 9.3.3.2.3. By End User
10. Middle East and Africa Hypercholesterolemia Treatment Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Disease Type
- 10.2.2. By Treatment Type
- 10.2.3. By End User
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Hypercholesterolemia Treatment Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Disease Type
- 10.3.1.2.2. By Treatment Type
- 10.3.1.2.3. By End User
- 10.3.2. Saudi Arabia Hypercholesterolemia Treatment Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Disease Type
- 10.3.2.2.2. By Treatment Type
- 10.3.2.2.3. By End User
- 10.3.3. UAE Hypercholesterolemia Treatment Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Disease Type
- 10.3.3.2.2. By Treatment Type
- 10.3.3.2.3. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. PESTLE Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product
15. Competitive Landscape
- 15.1. Amgen Inc
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
- 15.1.6. Key Personnel Details
- 15.1.7. SWOT Analysis
- 15.2. Amryt Pharma plc
- 15.3. AstraZeneca Plc.
- 15.4. Regeneron Pharmaceuticals, Inc.
- 15.5. Novartis Pharmaceuticals Corporation
- 15.6. Teva Pharmaceutical Industries Ltd.
- 15.7. Cipher Pharmaceuticals Inc.
- 15.8. Pfizer Inc.
- 15.9. Merck & Co., Inc.
- 15.10. Sun Pharmaceutical Industries Limited
16. Strategic Recommendations
17. About Us & Disclaimer
